17:26 EDT Anixa Biosciences (ANIX) files $200M mixed securities shelf
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Promising Advancements and Strategic Positioning Propel Anixa Biosciences to a Buy Rating
- Anixa completes dosing of fourth cohort in Phase 1 trial of CAR-T/CER-T therapy
- Anixa receives notice of allowance in China for cancer vaccine technology patent
- Anixa Biosciences treats second patient in fourth ovarian cancer trial cohort
- Anixa Biosciences issued additional U.S. patent for CAR-T technology